论文部分内容阅读
目的 :探讨肝细胞癌患者血清 IL- 12水平的变化及细胞免疫功能状态。方法 :应用 EL ISA方法和流式细胞仪技术分别检测了 60名 HCC患者和 15例良性肝病对照患者血清 IL - 12水平和外周血 T淋巴细胞亚群。结果 :HCC患者血清 IL- 12水平显著性下降 ,CD+ 3、CD+ 4细胞下降 ,CD+ 8细胞升高 ,CD+ 4/ CD+ 8比值下降。IL- 12水平和 CD+ 4/ CD+ 8比值随 HCC分期升高而降低。IL- 12水平和 CD+ 4/ CD+ 8比值有显著性正相关。结论 :HCC患者细胞免疫功能受抑制。血清IL - 12水平在评价 HCC患者的细胞免疫功能、手术效果及预后方面有重要作用。 IL - 12在减慢 HCC恶化进程方面可能发挥重要作用
Objective: To investigate the changes of serum IL-12 and the cellular immune function in patients with hepatocellular carcinoma. Methods: The levels of IL - 12 and T lymphocyte subsets in peripheral blood of 60 patients with HCC and 15 patients with benign liver disease were detected by ELISA and flow cytometry respectively. Results: Serum levels of IL-12 in HCC patients significantly decreased, while CD + 3 and CD + 4 cells decreased, CD + 8 cells increased, and the ratio of CD + 4 / CD + 8 decreased. The levels of IL-12 and CD + 4 / CD + 8 decreased with the increase of HCC staging. There was a significant positive correlation between the level of IL-12 and the ratio of CD + 4 / CD + 8. Conclusion: The cellular immunity of HCC patients is inhibited. Serum IL - 12 levels play an important role in evaluating cellular immune function, surgical outcome and prognosis in HCC patients. IL - 12 may play an important role in slowing the progression of HCC